Development of Myeloperoxidase Inhibitors to Treat Alzheimer's Disease

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$521,453.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43AG040935-01A1
Agency Tracking Number:
R43AG040935
Solicitation Year:
2012
Solicitation Topic Code:
NIA
Solicitation Number:
PA11-096
Small Business Information
TORREY PINES PHARMACEUTICALS, INC.
449 PINE NEEDLES DR, DEL MAR, CA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
809869840
Principal Investigator:
RICHARD MAKI
(858) 481-8547
richmaki@gmail.com
Business Contact:
RICHARD MAKI
(858) 481-8547
richmaki@gmail.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): The overall goal of the proposed research is to develop orally active inhibitors of myeloperoxidase MPO as a treatment forAlzheimer's disease. MPO is an abundant enzyme in leukocytes but its expression can be induced inastrocytes in Alzheimer's disease. This abnormal expression of MPO can lead to the oxidation of lipids and proteins leading to tissue damage and cell death resulting in loss of memory. A potent and safe inhibitor of MPO could be helpful in the treatment of Alzheimer's disease. We have developed novel mouse model to evaluate the role of MPO in Alzheimer's disease. In Specific Aim 1 We propose to improve the potency of hits identified in a screen looking for inhibitors of MPO. In Specific Aim 2 we propose totest several of the MPO inhibitors in a mouse model of Alzheimer's disease. The mice will be evaluated using both biochemical and behavioral/cognitive tests. PUBLIC HEALTH RELEVANCE: Myeloperoxidase is recognized as an important causative contributory agent in inflammatory diseases including Alzheimer's disease. An inhibitor of myeloperoxidase would provide a novel therapeutic agent that could be used to lower the level of oxidative damage that occurs in Alzheimer's disease. The experiments outlined in this Phase I SBIR application will help set the stage for the development of a novel and safe myeloperoxidase inhibitor for clinical use.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government